Respiratory disease testing market size exceeds 40 billion yuan, MGI Tech Co., Ltd. (688114.SH) provides influenza monitoring equipment to various disease control centers.

Recently, there has been a high incidence of flu in many parts of the country. According to the latest data from the Chinese Center for Disease Control and Prevention, the positivity rate for flu viruses is continuously increasing. The annual spread of flu viruses has also become a key application scenario for genetic sequencing equipment. According to calculations by relevant agencies, from 2019 to 2023, the market size of the respiratory disease testing industry will increase from 78.21 billion yuan to 120.96 billion yuan, with a compound annual growth rate of 11.52% during this period. The agency predicts that from 2024 to 2028, the market size of the respiratory disease testing industry will increase from 148.69 billion yuan to 404.81 billion yuan, with a compound annual growth rate of 28.45%. In the prevention and control of flu viruses, high-throughput genetic sequencing technology plays a crucial role. It can quickly provide early warnings for novel flu viruses, optimize flu vaccine deployment strategies, and provide key insights into monitoring flu trends. MGI Tech Co., Ltd. (688114.SH) has developed a combination of respiratory microbiome genome sequencing products with its deep high-throughput sequencing technology. The MGIEasy Respiratory Microbiome Genome Library Preparation Reagent Kit, paired with MGI Tech Co., Ltd.'s DNBSEQ sequencer platforms of different throughputs, and the MGI FluTrack basic analysis system loaded on the MGI Tech Co., Ltd. bioinformatics accelerator module MegaBOLT server, can accurately identify the subtype of flu virus in samples and obtain complete flu virus genome sequences. This product combination provides efficient and rapid flu virus tracking and tracing tools for disease control departments and research institutions. Additionally, real-time monitoring and dynamic analysis of the full genome sequences of flu viruses can more accurately capture the development trends of flu outbreaks, issue timely warnings of new or highly pathogenic variants, and formulate more scientific and precise prevention and control strategies. Currently, disease control centers in many parts of the country have begun to use MGI Tech Co., Ltd.'s respiratory microbiome genome sequencing product combination to strengthen monitoring and research on the flu. For example, disease control centers in cities such as Tongling, Ma'anshan, Bozhou, and Xuancheng in Anhui Province have deployed flu virus sequencing work using MGI Tech Co., Ltd.'s respiratory microbiome genome sequencing product combination. Respiratory disease testing is becoming a normalized demand and experiencing ultra-high-speed growth. With the increasing demand for sequencing instruments from disease control departments and research institutions, as well as the entry of downstream manufacturers, companies that master core technologies and achieve integration of reagents and instruments can often generate higher product added value and obtain greater profits in the market competition.